Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ

Skin Cancer

Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma

Ann Oncol

Rawson RV, Maher NG, Menzies AM, Lo SN, Ardakani NM, Jackett LA, Vergara IA, Pennington TE, Shannon KF, Ch'ng S, Gonzalez M, Burton EM, Lucas MW, Reijers ILM, Rozeman EA, Gyorki DE, Sandhu S, Carlino MS, Howle J, Khattak M, Van der Westhuizen A, Andrews MC, Atkinson V, van Akkooi ACJ, Spillane AJ, Saw RPM, van de Wiel BA, Blank CU, Long GV, Tetzlaff MT, Scolyer RA

doi: 10.1016/j.annonc.2025.10.1237

Lymphoma

Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial

Am J Hematol

Durmo R, Chauvie S, Minoia C, Bergesio F, Fallanca F, Peano S, Marcheselli L, Anastasia A, Boccomini C, Corradini P, Olivieri J, Arcaini L, Cavallo F, Ibatici A, Nassi L, Tarantino V, Pinto A, Stelitano C, Pulsoni A, Ricci F, Mancuso S, Cencini E, Di Renzo N, Mannarella C, Palmas A, Zinzani P, Bocci C, Rossi F, Carella AM, Federico M, Versari A, Guerra L, Luminari S

doi: 10.1002/ajh.27711

Gynecologic Cancer

Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45

Ann Oncol

Kristeleit RS, Ghamande S, Lisyanskaya A, Oaknin A, Prendergast E, Kim YB, Pradera JF, Littell RD, Gao B, Valabrega G, O'Malley DM, Dean A, Pisano C, Buscema J, Provencher D, Zagouri F, Martin LP, Chou HH, Demirkiran F, Ueland F, Chudecka-Głaz A, Yeku O, Beiner M, Anderson C, Drochytek V, Eskander RN, Agarwal R, Maloney L, Despain D, Connor C, Craib M, Shih D, Fujiwara K, Monk BJ

doi: 10.1016/j.annonc.2025.10.007

CHICAGO 2025

Genitourinary Cancer

ENZA-p: PSMA tumor volume predicts survival benefit from adding Lu-PSMA-617 to enzalutamide in high-volume, high-risk mCRPC

Central Nervous System Tumors

RANO seizure working group-Tumor Related Epilepsy Assessment Tool (RANO-TREAT) to assess seizure control for glioma treatment trials and clinical practice

Neuro Oncol

Avila EK, Reiner AS, Armstrong TS, Aaroe AE, Cunningham EM, Brown JG, Bruno F, Diarte J, Haggiagi A, Harrison RA, Joanta-Gomez A, Koekkoek JAF, Lee EQ, Le Rhun E, Miller H, Panageas KS, Peguero EN, Ruda R, Soffietti R, Templer JW, Tobochnik S, Vera E, Vogelbaum MA, Weller M, van den Bent M

doi: 10.1093/neuonc/noaf165

Genitourinary Cancer

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ cell tumors

Ann Oncol

Matulewicz RS, Baky F, Liso N, Williams BM, Porwal S, Assel M, Carver BS, Bajorin DF, Motzer RJ, Bosl GJ, McHugh DJ, Reuter VE, Tickoo SK, Al-Ahmadie H, Vickers AJ, Funt SA, Feldman DR, Sheinfeld J

doi: 10.1016/j.annonc.2025.03.002

Central Nervous System Tumors

High peritumoral network connectedness in glioblastoma reveals a distinct epigenetic signature and is associated with decreased overall survival

Neuro Oncol

Jütten K, Ort J, Kernbach JM, Meyer-Baese A, Meyer-Baese U, Hamou HA, Clusmann H, Wiesmann M, Bremer J, Koch H, Bak A, Ricklefs F, Drexler R, Heiland DH, Delev D

doi: 10.1093/neuonc/noaf101

Multiple Myeloma (MM)

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

J Clin Oncol

Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, Orfao A, Moreau P, Sonneveld P, Kumar SK, Dixon JG, Patel R, Bartlett BJ, Schecter J, McCarthy P, Hose D, Seckinger A, Mattia D, Goldschmidt H, Oliva S, Owen RG, Anderson KC, San-Miguel J, Durie BGM, Munshi N, International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group

doi: 10.1200/JCO-24-02020

Gastrointestinal Cancer

Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status

J Clin Oncol

Wankhede D, Halama N, Kloor M, Brenner H, Hoffmeister M

doi: 10.1200/JCO-25-00148

Related content

Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma

Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial

Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45

ENZA-p: PSMA tumor volume predicts survival benefit from adding Lu-PSMA-617 to enzalutamide in high-volume, high-risk mCRPC

RANO seizure working group-Tumor Related Epilepsy Assessment Tool (RANO-TREAT) to assess seizure control for glioma treatment trials and clinical practice

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ cell tumors

High peritumoral network connectedness in glioblastoma reveals a distinct epigenetic signature and is associated with decreased overall survival

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status